Literature DB >> 34535804

Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival.

Qiang-Wei Wang1,2, Zhao-Shi Bao3,2, Tao Jiang3,4,2, Yong-Jian Zhu5.   

Abstract

Tumor microenvironment (TME) is a complex and dynamic evolving environment which facilitates tumor proliferation and progression. We aimed at investigating the characteristics of tumor microenvironment and its prognostic value in gliomas. Transcriptome data of 702 glioma samples from The Cancer Genome Atlas were included as training dataset, while 325 samples from Chinese Glioma Genome Atlas database and 268 samples from GSE16011 database were used to validate. We found that the infiltration of stromal and immune cell varied in gliomas of different grades and pathological types, and was associated with poor prognosis. Based on the gene expression profile, we constructed a TME-related signature (TMERS), which was closely related to clinical features and genomic variation of gliomas. In TMERS-high group, specific gene mutations and increased copy number alternations were observed. Kaplan-Meier survival and Cox regression analysis showed that TMERS was an independent prognostic indicator. Then we developed a nomogram prognostic model to predict 1-year, 3-year and 5-year survival of patients. Functional analysis confirmed that TMERS could reflect the status of glioma microenvironment, and immunological analysis showed that macrophages were significantly enriched in the TMERS-high group. We established a novel TME-related signature for predicting prognosis and provided new insights into immunotherapy.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Genetic; Gliomas; Signature; Survival; Tumor microenvironment

Mesh:

Year:  2021        PMID: 34535804     DOI: 10.1007/s00262-021-03058-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  31 in total

1.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Authors:  Junfei Zhao; Andrew X Chen; Robyn D Gartrell; Andrew M Silverman; Luis Aparicio; Tim Chu; Darius Bordbar; David Shan; Jorge Samanamud; Aayushi Mahajan; Ioan Filip; Rose Orenbuch; Morgan Goetz; Jonathan T Yamaguchi; Michael Cloney; Craig Horbinski; Rimas V Lukas; Jeffrey Raizer; Ali I Rae; Jinzhou Yuan; Peter Canoll; Jeffrey N Bruce; Yvonne M Saenger; Peter Sims; Fabio M Iwamoto; Adam M Sonabend; Raul Rabadan
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

2.  Clinical practice guidelines for the management of adult diffuse gliomas.

Authors:  Tao Jiang; Do-Hyun Nam; Zvi Ram; Wai-Sang Poon; Jiguang Wang; Damdindorj Boldbaatar; Ying Mao; Wenbin Ma; Qing Mao; Yongping You; Chuanlu Jiang; Xuejun Yang; Chunsheng Kang; Xiaoguang Qiu; Wenbin Li; Shaowu Li; Ling Chen; Xuejun Li; Zhixiong Liu; Weimin Wang; Hongmin Bai; Yu Yao; Shouwei Li; Anhua Wu; Ke Sai; Guilin Li; Kun Yao; Xinting Wei; Xianzhi Liu; Zhiwen Zhang; Yiwu Dai; Shengqing Lv; Liang Wang; Zhixiong Lin; Jun Dong; Guozheng Xu; Xiaodong Ma; Wei Zhang; Chuanbao Zhang; Baoshi Chen; Gan You; Yongzhi Wang; Yinyan Wang; Zhaoshi Bao; Pei Yang; Xing Fan; Xing Liu; Zheng Zhao; Zheng Wang; Yiming Li; Zhiliang Wang; Guanzhang Li; Shengyu Fang; Lianwang Li; Yanwei Liu; Shuai Liu; Xia Shan; Yuqing Liu; Ruichao Chai; Huimin Hu; Jing Chen; Wei Yan; Jinquan Cai; Hongjun Wang; Lingchao Chen; Yuan Yang; Yu Wang; Lei Han; Qixue Wang
Journal:  Cancer Lett       Date:  2020-11-06       Impact factor: 8.679

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 4.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 6.  Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.

Authors:  Jonathan M Pitt; Marie Vétizou; Romain Daillère; María Paula Roberti; Takahiro Yamazaki; Bertrand Routy; Patricia Lepage; Ivo Gomperts Boneca; Mathias Chamaillard; Guido Kroemer; Laurence Zitvogel
Journal:  Immunity       Date:  2016-06-21       Impact factor: 31.745

7.  PABPC1 relevant bioinformatic profiling and prognostic value in gliomas.

Authors:  Qiangwei Wang; Zhiliang Wang; Zhaoshi Bao; Chuanbao Zhang; Zheng Wang; Tao Jiang
Journal:  Future Oncol       Date:  2019-12-04       Impact factor: 3.404

8.  Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.

Authors:  Wei Yan; Wei Zhang; Gan You; Zhaoshi Bao; Yongzhi Wang; Yanwei Liu; Chunsheng Kang; Yongping You; Lei Wang; Tao Jiang
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

Review 9.  Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.

Authors:  Anna C Filley; Mario Henriquez; Mahua Dey
Journal:  Oncotarget       Date:  2017-10-06

10.  Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas.

Authors:  Zheng Zhao; Fanlin Meng; Wen Wang; Zheng Wang; Chuanbao Zhang; Tao Jiang
Journal:  Sci Data       Date:  2017-03-14       Impact factor: 6.444

View more
  3 in total

1.  Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance.

Authors:  Qiang-Wei Wang; Wei-Wei Lin; Yong-Jian Zhu
Journal:  Cell Commun Signal       Date:  2022-01-09       Impact factor: 5.712

2.  Integrated Analysis of Genes Associated With Immune Microenvironment and Distant Metastasis in Uveal Melanoma.

Authors:  Wenchuan Zhou; Jing Li
Journal:  Front Cell Dev Biol       Date:  2022-03-30

3.  SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.

Authors:  Wei Yang; Bing Han; Yecheng Chen; Feng Geng
Journal:  Aging (Albany NY)       Date:  2022-08-13       Impact factor: 5.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.